| human | Q5 |
| P2798 | Loop ID | 95804 |
| P3835 | Mendeley person ID | claudia-kuntner |
| P496 | ORCID iD | 0000-0002-5988-1434 |
| P3829 | Publons author ID | 2530484 |
| P1053 | ResearcherID | F-6049-2014 |
| P1153 | Scopus author ID | 55894169700 |
| P69 | educated at | TU Wien | Q689400 |
| Medical University of Vienna | Q700731 | ||
| P108 | employer | CERN | Q42944 |
| Medical University of Vienna | Q700731 | ||
| Austrian Institute of Technology | Q783627 | ||
| P734 | family name | Kuntner | Q12794467 |
| Kuntner | Q12794467 | ||
| Kuntner | Q12794467 | ||
| P735 | given name | Claudia | Q2936353 |
| Claudia | Q2936353 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q37177013 | (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP. |
| Q48906492 | 18F, 11C and 68Ga in small animal PET imaging. Evaluation of partial volume correction methods. |
| Q36809104 | 32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016 |
| Q36935382 | A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer |
| Q33751254 | A new fast and fully automated software based algorithm for extracting respiratory signal from raw PET data and its comparison to other methods |
| Q36386154 | A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier |
| Q36955931 | A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier |
| Q48513004 | Abstracts of the 33rd International Austrian Winter Symposium : Zell am See, Austria. 24-27 January 2018. |
| Q59726747 | Advances in the scintillation performance of LuYAP:Ce single crystals |
| Q33466415 | Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. |
| Q50901303 | Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats. |
| Q50885351 | Automated electrophilic radiosynthesis of [¹⁸F]FBPA using a modified nucleophilic GE TRACERlab FXFDG. |
| Q50950710 | Automated radiosynthesis of [(18)F]ciprofloxacin. |
| Q52149526 | Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib. |
| Q47296127 | Design, Synthesis, and Evaluation of a Low-Molecular-Weight (11)C-Labeled Tetrazine for Pretargeted PET Imaging Applying Bioorthogonal in Vivo Click Chemistry |
| Q35985746 | Development and performance test of an online blood sampling system for determination of the arterial input function in rats |
| Q48087258 | Development of Fluorine-18 Labeled Metabolically Activated Tracers for Imaging of Drug Efflux Transporters with Positron Emission Tomography |
| Q48681676 | Development of a (18) F-labeled tetrazine with favorable pharmacokinetics for bioorthogonal PET imaging. |
| Q59726735 | Development of an optimized LSO/LuYAP phoswich detector head for the Lausanne ClearPET demonstrator |
| Q36949815 | Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. |
| Q36049576 | Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography |
| Q39516398 | Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake |
| Q30275741 | Guidance for Efficient Small Animal Imaging Quality Control |
| Q40017032 | Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice |
| Q89249430 | Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[11C]Methylpurine in Mice |
| Q47845084 | Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice |
| Q36949407 | Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography |
| Q38195959 | Kinetic modeling in pre-clinical positron emission tomography |
| Q39873732 | Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease |
| Q92725897 | Measurement of cerebral ABCC1 transport activity in wild-type and APP/PS1-21 mice with positron emission tomography |
| Q33605798 | Multimodality rodent imaging chambers for use under barrier conditions with gas anesthesia |
| Q38731582 | On the applicability of [18F]FBPA to predict L-BPA concentration after amino acid preloading in HuH-7 liver tumor model and the implication for liver boron neutron capture therapy |
| Q34100185 | Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data |
| Q36462753 | Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography |
| Q92939635 | Plasma pharmacokinetic and metabolism of [18F]THK-5317 are dependent on sex |
| Q40213366 | Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. |
| Q48453239 | Preclinical in vitro &in vivo evaluation of [(11)C]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1. |
| Q59726120 | Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [ 18 F]FBPA in human and mouse tumour cell lines |
| Q58559917 | Quantitative preclinical PET imaging: opportunities and challenges |
| Q59726581 | Radiosynthesis and Assessment of Ocular Pharmacokinetics of 124I-Labeled Chitosan in Rabbits Using Small-Animal PET |
| Q36949859 | Radiosynthesis and in vivo evaluation of 1-[18F]fluoroelacridar as a positron emission tomography tracer for P-glycoprotein and breast cancer resistance protein |
| Q47956682 | Radiosynthesis of [124I]iodometomidate and biological evaluation using small-animal PET. |
| Q61799131 | Real-time data-driven motion correction in PET |
| Q92235870 | Reproducibility and Comparability of Preclinical PET Imaging Data: A Multicenter Small-Animal PET Study |
| Q59726819 | Scintillation Properties of Mixed LuYAP Crystals in View of Their Use in a Small Animal PET Scanner in Phoswich Configuration |
| Q36949086 | Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor |
| Q36949864 | Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate |
| Q38747004 | Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[18F]fluoro-β-d-allofuranosyl)-2-nitroimidazole (β-6'-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia |
| Q36949082 | Synthesis and preclinical evaluation of the radiolabeled P-glycoprotein inhibitor [(11)C]MC113. |
| Q36949089 | Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier |
| Q59726706 | Synthesis of a [18F]fluorobenzothiazole as potential amyloid imaging agent |
| Q39213026 | Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study |
| Q36949854 | Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. |
| Q59726762 | The ClearPET™ project: development of a 2nd generation high-performance small animal PET scanner |
| Q37185659 | The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study |
| Q53470306 | Validation of PET-SORTEO Monte Carlo simulations for the geometries of the MicroPET R4 and Focus 220 PET scanners. |
| Q98155144 | Vitamin K3 chloroderivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis and inhibits aggresome formation in hepatocellular carcinoma cells |
| Q41139974 | [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier |
| Q38701499 | [11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice. |
| Q35148312 | [18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents |
| Q50545531 | [18F]Fluoroalkyl azides for rapid radiolabeling and (Re)investigation of their potential towards in vivo click chemistry. |
Search more.